These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677 [TBL] [Abstract][Full Text] [Related]
4. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682 [TBL] [Abstract][Full Text] [Related]
8. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180 [TBL] [Abstract][Full Text] [Related]
9. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
10. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. van Dijk E; Biesma HD; Cordes M; Smeets D; Neerincx M; Das S; Eijk PP; Murphy V; Barat A; Bacon O; Prehn JHM; Betge J; Gaiser T; Fender B; Meijer GA; McNamara DA; Klinger R; Koopman M; Ebert MPA; Kay EW; Hennessey BT; Verheul HMW; Gallagher WM; O'Connor DP; Punt CJA; Loupakis F; Lambrechts D; Byrne AT; van Grieken NCT; Ylstra B J Clin Oncol; 2018 Jul; 36(20):2052-2060. PubMed ID: 29792754 [TBL] [Abstract][Full Text] [Related]
11. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Jang HJ; Kim BJ; Kim JH; Kim HS Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145 [TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393 [TBL] [Abstract][Full Text] [Related]
14. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327 [TBL] [Abstract][Full Text] [Related]
15. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D; Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309 [TBL] [Abstract][Full Text] [Related]
17. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer. Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485 [TBL] [Abstract][Full Text] [Related]
18. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097 [TBL] [Abstract][Full Text] [Related]
19. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S J BUON; 2013; 18(1):116-23. PubMed ID: 23613396 [TBL] [Abstract][Full Text] [Related]
20. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]